Cost savings in asthma management when using NIOX MINO® First health economic study published

Cost savings in asthma management when using NIOX MINO® First health economic
study published

SOLNA - 14 January, 2008 - Aerocrine AB (OMX Nordic Exchange: AERO) reports that
the first heath economic study evaluating the effect of introducing measurements
of exhaled NO in asthma management has been published.

The objective of the study was to assess the impact on direct costs for asthma
management in Germany when NIOX MINO is purchased and used.

The study is based on an estimated future reimbursement of 32 Euro per exhaled
NO test. The study shows that regular measurements of exhaled NO with NIOX MINO
in asthma patients using inhaled corticosteroids result in a cost saving of 30
Euro per patient and year. In patients with more severe asthma, the use of NIOX
MINO resulted in a cost saving of 160 Euro per patient and year.

The cost savings were achieved as a result of therapy being optimally adjusted
based on NIOX MINO test results. Incorporating measurements of exhaled NO, the
number of acute hospital visits was reduced and lower doses of anti-inflammatory
medication were required to keep the patient's asthma controlled. The
introduction of regular measurements of exhaled NO balances the costs incurred
for the tests performed with NIOX MINO and generates a cost saving.

The article has been e-published ahead of print in Respiratory Medicine.  

”The fact that exhaled NO measurements reduce the overall cost of therapy as
well as dramatically improve airway disease management is of significant
importance both for the patient and for the continued establishment of exhaled
NO in clinical practice,” says Paul de Potocki, CEO Aerocrine.


For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82

About Aerocrine
Aerocrine AB (publ) is a medical technology concern focused on the improved
management and care of patients with airway inflammation. Aerocrine shares were
listed on the Stockholm Stock Exchange on 15 June 2007. The company markets
NIOX® Flex globally, and also markets NIOX MINO® - which represents a new
generation of hand-held products - in Europe. Both products enable fast and
reliable management of airway inflammation and may therefore play a critical
role in more effective diagnosis, treatment and follow-up of asthma patients.
Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
8 am on January the 14th, 2008.